Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Down 6.1% in November

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a large drop in short interest in November. As of November 30th, there was short interest totalling 1,230,000 shares, a drop of 6.1% from the November 15th total of 1,310,000 shares. Based on an average trading volume of 712,600 shares, the short-interest ratio is currently 1.7 days. Approximately 3.8% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL traded down $0.03 during midday trading on Tuesday, reaching $1.64. The stock had a trading volume of 177,727 shares, compared to its average volume of 380,987. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29. The stock has a market cap of $72.86 million, a P/E ratio of -1.15 and a beta of 0.30. The firm has a fifty day simple moving average of $2.14 and a two-hundred day simple moving average of $2.34. Werewolf Therapeutics has a 12-month low of $1.58 and a 12-month high of $8.19.

Institutional Investors Weigh In On Werewolf Therapeutics

A number of hedge funds have recently added to or reduced their stakes in HOWL. Walleye Capital LLC lifted its holdings in shares of Werewolf Therapeutics by 10.7% in the 3rd quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock valued at $231,000 after buying an additional 10,528 shares during the period. American Century Companies Inc. lifted its holdings in Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after acquiring an additional 12,656 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Werewolf Therapeutics during the 3rd quarter worth $29,000. Point72 DIFC Ltd acquired a new position in shares of Werewolf Therapeutics during the 2nd quarter worth $34,000. Finally, XTX Topco Ltd acquired a new position in Werewolf Therapeutics during the third quarter worth about $45,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.